D-1553

Small molecule

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

D-1553 is one of 52 small molecule programs targeting Lung Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06300177

Phase 1/2Not yet recruiting

KRAS G12C Mutant Advanced Solid Tumors

NCT06435455

Clinical

Trials by Indication[1]

Solid Tumors2 trials

Study to Evaluate D-1553 in Subjects With Solid Tumors

Active, not recruiting·IInventisBio Co., Ltd·Phase 1/2·NCT04585035·180 enrolled

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Active, not recruiting·IInventisBio Co., Ltd·Phase 1/2·NCT05379946·92 enrolled

Non-Small Cell Lung Cancer2 trials

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Terminated·IInventisBio Co., Ltd·Phase 1/2·NCT05492045·22 enrolled

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06300177·522 enrolled

Lung Cancer1 trial

Study to Evaluate D-1553 in Subjects With Lung Cancer

Completed·IInventisBio Co., Ltd·Phase 1/2·NCT05383898·225 enrolled

KRAS G12C Mutant Advanced Solid Tumors1 trial

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Not yet recruiting·SSuzhou Genhouse Bio Co., Ltd.·Phase 1/2·NCT06435455·126 enrolled

Midazolam1 trial

A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Completed·IInventisBio Co., Ltd·Phase 1·NCT06105255·45 enrolled

1 more indication

Adult1 trial

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

Completed·IInventisBio Co., Ltd·Phase 1·NCT06233916·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for D-1553. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-1553 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-1553. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

D-1553

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Solid Tumors2 trials

Non-Small Cell Lung Cancer2 trials

Lung Cancer1 trial

KRAS G12C Mutant Advanced Solid Tumors1 trial

Midazolam1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News